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MP 824, Southampton General Hospital (600 mM NaCl) buffer (not shown).
We then sought to determine whether the Hdm2:Southampton SO16 6YD
United Kingdom hCtBP2 interaction can be detected in vivo. Hdm2 and
either Myc epitope-tagged hCtBP2 or Myc--galactosi-
dase control were transiently overexpressed in HEK 293
cells and cell lysates subjected to immunoprecipitationSummary
with anti-Myc antibody. Hdm2 protein was coimmuno-
precipitated from the Myc-hCtBP2-containing lysatesThe transcription factor p53 lies at the center of a
protein network that controls cell cycle progression but not the Myc--galactosidase control (see Supple-
mental Data). Similar coimmunoprecipitation experi-and commitment to apoptosis [1]. p53 is inactive in
proliferating cells, largely because of negative regula- ments were performed on nontransfected MCF-7 cell
lysates with anti-CtBP antibody. Hdm2 coimmunopreci-tion by the Hdm2/Mdm2 oncoprotein, with which it
physically associates. Release from this negative reg- pitated specifically with the anti-CtBP antibody, but not
in control precipitations (Figure 1B), demonstrating aulation is sufficient to activate p53 [2] and can be trig-
gered in cells by multiple stimuli through diverse path- naturally occurring interaction between endogenous
Hdm2 and hCtBP2 proteins in vivo.ways [3–5]. This diversity is achieved in part because
Hdm2 uses multiple mechanisms to inactivate p53; it hCtBP2 is a 445 amino acid protein that shares 83%
sequence similarity with its homolog, hCtBP1. Both pro-targets p53 for ubiquitination and degradation by the
proteosome [6–8], shuttles it out of the nucleus and teins have orthologs in the mouse, whereas Xenopus
and Drosophila each express a single CtBP moleculeinto the cytoplasm [9, 10], prevents its interaction with
transcriptional coactivators [11], and contains an in- [13, 14]. All CtBP proteins contain a highly conserved
central domain with significant sequence similarity to atrinsic transcriptional repressor activity [12]. Here we
show that Hdm2 can also repress p53 activity through family of D-isomer-specific 2-hydroxyacid dehydroge-
nases [13, 14]. This domain is located between aminothe recruitment of a known transcriptional corepres-
sor, hCtBP2 [13, 14]. This interaction, and consequent acids 106 and 353 in hCtBP2. The N terminus of CtBP
family members contains a protein:protein interactionrepression of p53-dependent transcription, is relieved
under hypoxia or hypoxia-mimicking conditions that domain, through which they are recruited to proteins
containing a consensus PXDLS motif [16, 17]. We usedare known to increase levels of intracellular NADH.
CtBP proteins can undergo an NADH-induced confor- GST “pull-down” assays to test a series of GST-hCtBP2
deletion mutants for their ability to bind Hdm2 (Figuremational change [15], which we show here results in
a loss of their Hdm2 binding ability. This pathway rep- 1C). A mutant containing amino acids 1–110 pulled down
Hdm2 as effectively as the full-length protein (lane 5),resents a novel mechanism whereby p53 activity can
be induced by cellular stress. whereas one containing amino acids 110–445 did not
pull down Hdm2 (lane 3). Therefore, the N-terminal do-
main of hCtBP2 is both necessary and sufficient for theResults and Discussion
interaction with Hdm2. A mutant lacking the C-terminal
86 amino acids (construct 1–359, lane 2) consistentlyScreening of a human HeLa cell cDNA expression library
with recombinant Hdm2 protein identified CtBP2 as a pulled down less Hdm2 than did the full-length protein,
despite the lack of any direct Hdm2 binding site in thispotential Hdm2 binding partner (not shown). A GST-
region (see lane 3). This latter finding is consistent withhuman CtBP2 (GST-hCtBP2) fusion protein, but not
previous reports that have indicated a regulatory roleother GST-fusion controls, was able to capture the 90
for the C terminus of CtBP-proteins on N-terminal pro-kDa Hdm2 protein from a partially purified bacterial ly-
tein:protein interactions [18, 19].sate (Figure 1A). Furthermore, when E. coli lysates that
To determine which domain of Hdm2 interacts withhad been induced to express human proteins (either
hCtBP2, we also constructed a panel of Hdm2 truncationp53 or Hdm2) were subjected to far-Western analysis
mutants. Hdm2(6–306) bound the N-terminal domain ofwith GST-hCtBP2 as a probe, a 90 kDa band was de-
hCtBP2 (Figure 1D, lane 3), albeit less strongly than full-tected only in Hdm2-containing lysates (see Supple-
length Hdm2, whereas Hdm2(6–210) did not bind (lanemental Data). These experiments demonstrate that
2). The Hdm2 section containing amino acids 210–306Hdm2 and hCtBP2 can associate specifically in vitro.
that these experiments identify as being required for
hCtBP2 binding primarily consists of the acidic domain,
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Figure 1. Hdm2 Interacts with hCtBP2 In Vitro and In Vivo
(A) Partially purified recombinant Hdm2 was incubated with the GST-fusion proteins indicated, and complexes were pulled down with
glutathione-sepharose beads. Samples were then analyzed by SDS-PAGE, followed by either Coomassie blue staining to demonstrate equal
amounts of GST-fusion protein or Western blotting with mAb 2A10 to detect Hdm2.
(B) Extracts from MCF-7 cells were immunoprecipitated with protein G beads alone (-), an irrelevant goat Ig to caspase 6 (control), or E16
goat-polyclonal antibody to CtBP. Precipitates were then analyzed by immunoblotting with rabbit polyclonal Ig R41 to hCtBP2 and Hdm2
mAb 2A9.
(C) Recombinant full-length GST-hCtBP2(1-445), GST-hCtBP2 deletion mutants, and GST alone were used as bait in GST pull-down assays
with equal amounts of full-length Hdm2. Coomassie blue staining confirmed that equivalent amounts of the CtBP2 mutants had been used
(upper panel), and immunoblotting with mAb 2A10 was used for detecting coprecipitated Hdm2 (lower panel). A comparison between the
mutants and the known domains of hCtBP2 is shown, with the N-terminal GST fusion omitted.
(D) GST-hCtBP2(1–110) was used to pull down the Hdm2 deletion mutants indicated. Equal amounts of input proteins were confirmed by
Western blotting with mAb 4B2 for Hdm2 and Coomassie blue staining for GST-hCtBP2(1–110). Coprecipitated Hdm2 was detected via
immunoblotting with mAb 4B2. The location of the Hdm2 deletion mutants with reference to known domains of Hdm2 are shown: P  p53
binding domain; NL/NE  Nuclear localization and export sequences; A  acidic region; Z  Zinc finger; R  RING finger.
homology with Hdm2 within the acidic domain and can PXDLS motif is regulated by changes in cellular redox
potential [15]. The central dehydrogenase domain ofalso interact with hCtBP2 in vitro (see Supplemental
Data). Furthermore, the hCtBP2 paralog, hCtBP1, is able hCtBP1 contains a high-affinity binding site for NADH
(GXGXXG, Figure 2A), occupation of which induces ato interact with Hdm2 in GST “pull-down” assays (see
Supplemental Data). conformational change in the hCtBP1 molecule and an
increase in binding to proteins such as E1A and ZEB.The recruitment of hCtBP1 by proteins containing a
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NAD ratio sufficient to promote binding of CtBP pro-
teins to PXDLS motif proteins in the cell. As shown
in Figure 2C, 200 M CoCl2 reduced the formation of
Hdm2:hCtBP2 complexes in MCF-7 cells. Hypoxia,
which has a greater effect on the cellular NADH/NAD
ratio than CoCl2 [15], was more effective than CoCl2
in reducing the Hdm2:hCtBP2 interaction (Figure 2C).
These data demonstrate, therefore, that the NADH-
induced regulation of the Hdm2:hCtBP2 interaction also
occurs in vivo.
To determine the functional consequences of the
Hdm2:hCtBP2 interaction, we examined whether over-
expression of either molecule would modify the function
of the other. Hdm2 regulates p53 levels in cells by direct-
ing the nuclear export of p53 and targeting it to the
ubiquitin-proteasome degradation pathway [6–10]. We
therefore tested whether Hdm2 could regulate hCtBP2
protein levels. HEK 293 cells were transiently trans-
fected with vectors encoding Myc-tagged hCtBP2, and
increasing amounts of Hdm2. Hdm2 did not decrease
hCtBP2 expression levels in this assay (see Supplemen-
tal Data), providing evidence that Hdm2 does not target
hCtBP2 for proteosome-mediated degradradation, nor
did it have an effect on the intracellular localization of
hCtBP2 in HEK 293 cells (data not shown). The most
well-documented function of CtBP proteins is as short-
range transcriptional corepressors [13, 14]. Thus, CtBP
proteins are recruited to promoters by sequence-spe-
Figure 2. The Hdm2:hCtBP2 Interaction Is Inhibited by NADH Bind- cific DNA binding transcription factors, either through a
ing to the hCtBP2 Dehydrogenase Domain direct physical interaction or indirectly through bridging
(A) Multiple sequence alignment of the conserved GXGXXG NAD/ proteins. We therefore tested whether the formation of
NADH binding site of hCtBP1, hCtBP2, and the human D-isomer- an Hdm2:hCtBP2 complex could modify the ability of
specific 2-hydroxyacid dehydrogenase enzyme (hD-2HADH). The Hdm2 to repress p53-dependent transcription. For this
affinity of the site in hCtBP1 has been reported to be approximately
experiment we used three different p53-responsive lu-100-fold greater for NADH than for NAD [15]. The arrow marks the
ciferase reporters: Bax-Luc, Hdm2-Luc03, and p21-Lucsite of the alanine substitution mutant in hCtBP2 (G189A).
(B) The interaction between Hdm2 and the indicated GST-hCtBP2 containing promoter regions from Bax, Hdm2, and
fusion proteins was determined by a GST pull-down assay in the p21WAF-1, respectively. In the presence of Hdm2, hCtBP2
presence of increasing concentrations of NADH. reproducibly repressed p53-dependent transcription
(C) MCF-7 cells were treated for 2 hr with 200 M CoCl2 or hypoxia from the Bax-Luc and Hdm2-Luc reporters but had no
(1% O2) where indicated. Cell lysates were immunoprecipitated
effect on p21-Luc (Figure 3A).(IP) with goat polyclonal anti-CTBP (E-16) or a control antibody
To confirm that the inhibition of p53-dependent tran-to caspase 6, and immunoprecipitated proteins were analyzed by
Western blot with antibodies for CtBP (R41) and Hdm2 (2A10). scription by hCtBP2 is dependent on a direct interaction
between Hdm2 and hCtBP2, we treated cells with CoCl2
to disrupt the Hdm2:hCtBP2 interaction. After CoCl2 ex-
A mutation in hCtBP1 in the GXGXXG motif (G183A) posure, hCtBP2 was no longer able to enhance Hdm2-
abolishes NADH responsiveness [15]. We noted that this mediated repression of p53-dependent transcription
site in hCtBP2 is conserved (amino acids 187–192) and (Figure 3B); this was not due to an effect on p53 protein
asked whether NADH could regulate the Hdm2:hCtBP2 levels in these cells (Figure S4 in the Supplemental Data).
interaction. NADH concentrations (0.01 to 1 mM) known This effect of CoCl2 was due to its specific effect on
to promote the interaction of hCtBP1 with PXDLS motif regulating intracellular NADH levels because repression
proteins inhibited binding of full-length GST-hCtBP2 to by the hCtBP2(G189A) mutant was unaffected by CoCl2
Hdm2 (Figure 2B, top panel). This inhibition did not occur (Figure 3C). In addition, we transfected cells with an
when either GST-hCtBP2(1–110), lacking the dehydro- Hdm2(1–210) mutant, which can bind p53, is localized
genase domain, or hCtBP2(G189A), containing a muta- in the nucleus, and can inhibit p53 activity but cannot
tion in the NADH binding site, were used in the assays bind hCtBP2. In the presence of Hdm2(1–210), hCtBP2
(Figure 2B, lower panels). Therefore, in contrast to inter- did not repress p53-dependent transcription. (Figure
actions with PXDLS motif proteins, the conformational 3D), confirming that an interaction between Hdm2 and
changes induced by NADH binding to the CtBP dehydro- hCtBP2 is required for hCtBP2 to be able to repress
genase domain result in a reduced affinity of hCtBP2 p53-dependent transcription.
for Hdm2. Exposure of cells in culture to CoCl2 can be One model that could account for our observation is
used as a model for the induction of a hypoxia-like stress that an Hdm2:hCtBP2 complex directly interacts with
response. Zhang et al. [15] have shown that CoCl2 treat- p53 to bring about repression of p53 transactivating
ability. The binding sites for p53 and hCtBP2 on Hdm2ment (200M) induces an increase in the cellular NADH/
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Figure 3. Recruitment of hCtBP2 by Hdm2 Results in Promoter-Selective Repression of p53-Dependent Transcription
(A) HEK 293 cells were transfected with 200 ng of the p53-dependent reporter vector containing p21WAF-1, Hdm2, or Bax promoter sequences,
25 ng of wild-type p53 expression vector, and 200 ng of Hdm2 expression vector to give conditions in which approximately 70% inhibition
of p53 activity by the cotransfected Hdm2 was achieved. Transfections also included 1 g of either pcDNA 3.1 (solid bars) or pcDNA3mychis
hCTBP2 (open bars) expression vectors. Relative luciferase activity (RLA) was first calculated by normalization to expression from a cotrans-
fected -galactosidase expression vector, and the RLA of each promoter in the presence of pcDNA3.1 was defined as 100%. In the absence
of p53, promoter activity was approximately 2%.
(B) HEK 293 cells were transfected with the Hdm2-Luc03 p53-responsive reporter vector (which contains only 165 bp of Hdm2 promoter
sequence including the two p53 response elements) and the indicated amounts of expression vector. Thirty hours after transfection, cells
were treated for 16 hr with 200 M CoCl2 before being assayed.
(C) Transfections were repeated as in (B), with the addition of the NADH-insensitive G189A mutant of hCtBP2.
(D) Hdm2-Luc03 reporter assays in HEK 293 cells were performed with the indicated vectors. hCtBP2(G189A) was used in this experiment
because it functions as a constitutively active mutant that is insensitive to variations in intracellular NADH.
are located in distinct domains, suggesting that a tri- to sites located within a short distance of the promoter
for repression to occur [17]. Consistent with this knownmeric complex of p53:Hdm2:hCtBP2 could form. Figure
4A demonstrates that, when combinations of Hdm2, property of CtBP proteins, the p53-responsive promot-
ers that were sensitive to inhibition by hCtBP2 (Bax-LucGST-hCtBP2(1–110), and p53 are coincubated in vitro,
p53 coprecipitates with GST-hCtBP2(1–110) only in the and Hdm2-Luc03) in this study both have p53 response
elements (p53-RE) situated within 500 bp of the tran-presence of Hdm2. Therefore, Hdm2 is able to recruit
hCtBP2 to p53. In this model (Figure 4B), the role of scription start site, whereas in the nonresponsive p21
promoter, the p53-RE is located further upstreamHdm2 as a bridging protein between hCtBP2 and p53
is analogous to the role played by CtIP in recruiting at 2400. It is important to consider, however, that the
mechanisms whereby CtBP represses transcription re-CtBP to BRCA1 [23]. Our model is further supported by
recent evidence that Hdm2 can be recruited to p53- main largely undefined and may depend on the context
of individual promoters. Specifically, CtBP proteins canresponsive promoters through p53 binding [24]. The pro-
moter specificity of this effect in our assays may reflect recruit histone deacetylase proteins, including HDAC1
[25, 26], and repression by CtBP can be either depen-the known requirement for CtBP proteins to be recruited
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nous Hdm2 levels are very low, and under conditions
of chemotherapeutic drug exposure, which would have
disrupted the interaction between Hdm2 and p53, and
they therefore may not have detected the effects that
we have demonstrated here. The authors also clearly
demonstrated that CtBP null MEFs are hypersensitive
to cell killing by a range of proapoptotic stimuli, with
clear implications for the role of CtBP family proteins in
tumor biology. Evidence that we have presented here
provides, in part, a mechanistic explanation for these
striking observations.
Hdm2 is emerging as a key regulator of cell-cycle
control and commitment to apoptosis [21]. The identifi-
cation of protein:protein interactions made by Hdm2
has resulted in a number of significant advances in our
understanding of how these processes can be con-
trolled by diverse cellular stimuli, such as the activation
of oncogenes [30] and ionizing radiation [4]. Several
Hdm2 binding proteins are also promising targets for
the design of novel cancer therapies [31]. Hypoxic stress
induces a p53-dependent apoptotic response and in
many types of cancer may be responsible for the posi-
tive growth advantage of tumor cells in which the p53
gene is mutated [32]. The mechanisms whereby hyp-Figure 4. Proposed Model of the Mechanism whereby Hdm2 Re-
oxia, and hypoxia-mimicking chemicals such as CoCl2cruits CtBP Proteins to Negatively Regulate p53-Dependent Tran-
scription and deferoxamine, induce p53-dependent apoptosis are
(A) Recombinant human p53, Hdm2, and GST-hCtBP2(1–110) were now beginning to be elucidated. There is evidence that
mixed as indicated and subjected to either GST pull-down analysis the mechanism may be either dependent or independent
or immunoprecipitation with mAb 2A9 to Hdm2. Coprecipitated p53 on the activation of p53s transactivation activity, de-
was detected with polyclonal antibody CM1. pending on the cell type being studied and the exact
(B) Model for the promoter-selective inhibition of p53-dependent
nature of the stress involved [5, 33]. Our finding thattranscription by CtBP proteins. Given the high degree of functional
hypoxia-mimicking conditions result in the dissociationhomology between hCtBP1 and hCtBP2 and the ability of the two
of Hdm2:hCtBP2 complexes, and a derepression of p53-proteins to form heterodimers, it is probable that hCtBP1 is also
dependent transcription, provides a significant advanceable to repress p53 activity by this mechanism.
in the understanding of these pathways.
CtBP family members interact with, and modify the
dent [16] or independent [27] of HDAC activity. Hdm2 activity of, a large number of proteins with key roles
has recently been shown to recruit HDAC1 to p53 though in development, differentiation, cell-cycle control, and
an undefined bridging protein, resulting in deacetylation apoptosis [13, 14, 34]. The majority of the interactions
of p53 and a reduction in the expression of p53 response that have been described to date are dependent on the
genes, including genes for Hdm2 and p21WAF-1 [28]. If presence of a PXDLS motif in the interacting protein. In
CtBP proteins function as this bridging molecule, then a recent two-hybrid analysis [35], however, 13 of 41
CtBP-interacting clones did not contain this motif, andthey could be predicted to have HDAC1-dependent in-
similarly, there is no PXDLS sequence in Hdm2. We havehibitory effects on promoters such as p21WAF-1, in addi-
demonstrated that the NADH-induced conformationaltion to the effects that were observed for the Hdm2 and
change that is known in CtBP family members to resultBax promoters in the absence of HDAC1 transfection.
in an increase in their affinity for PXDLS motif proteinsAlthough we have clearly demonstrated that a hyp-
causes a decrease in hCtBP2 binding to Hdm2 protein,oxia-regulated interaction occurs between endogenous
and we anticipate the discovery of other CtBP-proteinHdm2 and hCtBP2 proteins, our data defining the func-
interactions that are regulated by NADH in this way. Intional consequence of this interaction is dependent of
summary, our data demonstrates that NADH binding bythe analysis of synthetic reporter constructs. However,
CtBP proteins does not act as a simple on-off switchrecent analysis of gene expression profiles in mouse
for binding to one set of transcription factors but ratherembryo fibroblasts (MEFs) from CtBP1 and CtBP2 homo-
acts as a mechanism to regulate the differential recruit-zygous null animals has recently confirmed that CtBP
ment of CtBP by two distinct groups of proteins in thecan repress expression of a range of proapoptotic
cell.genes, including the p53 target genes bax, PERP, and
noxa [29]. Expression of all of these genes was upregu- Supplemental Data
lated in CtBP null MEFs and rerepressed when CtBP2 Supplemental Data including additional methodological details is
available with this article online at http://www.current-biology.com/was reexpressed in these cells. Reporter-based assays
cgi/content/full/13/14/1234/DC1/.performed by the authors of this recent manuscript led
them to conclude that this effect was independent of a
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